1/16
05:28 pm
atos
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy [Yahoo! Finance]
Low
Report
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy [Yahoo! Finance]
1/16
04:40 pm
atos
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy
High
Report
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy
1/16
06:47 am
atos
Atossa Therapeutics shares rise after FDA grants orphan drug designation for soft tissue sarcoma [Seeking Alpha]
Low
Report
Atossa Therapeutics shares rise after FDA grants orphan drug designation for soft tissue sarcoma [Seeking Alpha]
1/6
08:37 am
atos
Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer [Yahoo! Finance]
Medium
Report
Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer [Yahoo! Finance]
1/6
08:15 am
atos
Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer
Low
Report
Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer
12/17
08:21 am
atos
Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category [Yahoo! Finance]
Medium
Report
Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category [Yahoo! Finance]
12/17
08:15 am
atos
Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category
Low
Report
Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category
12/15
08:10 am
atos
Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium [Yahoo! Finance]
Low
Report
Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium [Yahoo! Finance]
12/15
08:00 am
atos
Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium
Medium
Report
Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium
12/11
10:37 am
atos
Atossa gains on Rare Pediatric Disease status for Duchenne asset [Seeking Alpha]
Medium
Report
Atossa gains on Rare Pediatric Disease status for Duchenne asset [Seeking Alpha]
12/11
08:17 am
atos
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy [Yahoo! Finance]
Medium
Report
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy [Yahoo! Finance]
12/11
08:00 am
atos
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy
Medium
Report
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy
12/9
08:00 am
atos
Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen
Low
Report
Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen
12/8
08:07 am
atos
Atossa Genetics (NASDAQ:ATOS) had its price target raised by analysts at Ascendiant Capital Markets from $7.75 to $8.00. They now have a "buy" rating on the stock.
Medium
Report
Atossa Genetics (NASDAQ:ATOS) had its price target raised by analysts at Ascendiant Capital Markets from $7.75 to $8.00. They now have a "buy" rating on the stock.
12/4
08:00 am
atos
Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum
Low
Report
Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum
12/2
08:00 am
atos
Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma
Medium
Report
Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma
11/17
09:22 am
atos
Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation [Yahoo! Finance]
Medium
Report
Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation [Yahoo! Finance]
11/17
09:07 am
atos
Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation
Medium
Report
Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation
11/12
08:38 am
atos
Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update [Yahoo! Finance]
Low
Report
Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update [Yahoo! Finance]
11/12
08:15 am
atos
Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Low
Report
Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
11/6
08:00 am
atos
Atossa Therapeutics Announces Acceptance of Four Abstracts Highlighting (Z)-Endoxifen Research for Presentation at the 2025 San Antonio Breast Cancer Symposium
Low
Report
Atossa Therapeutics Announces Acceptance of Four Abstracts Highlighting (Z)-Endoxifen Research for Presentation at the 2025 San Antonio Breast Cancer Symposium
10/24
12:16 pm
atos
Atossa Genetics (NASDAQ:ATOS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Atossa Genetics (NASDAQ:ATOS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/21
08:00 am
atos
Atossa Therapeutics Highlights Progress in RECAST™ DCIS Platform Trial at Early Detection Research Conference; Laura Esserman, MD, MBA, to Discuss Active-Surveillance Strategy and Novel Endocrine Agents
Low
Report
Atossa Therapeutics Highlights Progress in RECAST™ DCIS Platform Trial at Early Detection Research Conference; Laura Esserman, MD, MBA, to Discuss Active-Surveillance Strategy and Novel Endocrine Agents